Gonadorelin

Gonadorelin is a synthetic, FDA-approved copy of native GnRH, historically used for diagnostic pituitary testing (Factrel) and, via a dedicated pulsatile infusion pump, to induce ovulation (Lutrepulse, now discontinued in the US). Its physiological effect depends entirely on a pulse roughly every 60 to 120 minutes. Its now-common off-label use in testosterone replacement therapy protocols, injected two to three times weekly, does not reproduce that pulse pattern and has no dedicated randomized trial establishing that it preserves fertility or testicular function as intended.

Ask about Gonadorelin

Research snapshot

CategoryCurrent information
Peptide categoryGnRH (identical to native human GnRH)
Primary research interestDiagnostic pituitary testing (approved); historical pulsatile-pump ovulation induction (discontinued); off-label TRT-adjunct use (unstudied for that regimen)
Highest available evidenceTier 1 for the approved diagnostic use; Tier 5-6 (practitioner/community) for the off-label TRT-adjunct schedule
Human research availableYes for approved uses; no dedicated randomized trial for the twice/thrice-weekly TRT-adjunct injection schedule
Development statusApproved (Factrel); Lutrepulse (pulsatile pump, fertility) discontinued in the US
Regulatory statusFDA-approved (Factrel) for diagnostic pituitary function testing

Technical identity

Technical propertyInformation
Primary nameGonadorelin
Alternative namesGnRH, LHRH, Factrel (brand), Lutrepulse (brand, discontinued)
Peptide sequencepyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (decapeptide, identical to native human GnRH)
Amino-acid length10 residues
Molecular formulaC55H75N17O13
Molecular weight1182.31 g/mol
CAS Registry Number33515-09-2 (also 71447-49-9 diacetate, 51952-41-1 hydrochloride)
Chemical modificationsNone – identical sequence to native human GnRH
Peptide classGonadotropin-releasing hormone
Primary biological targetPituitary GnRH receptor (pulsatile stimulation of LH/FSH release)
Developer or originatorSynthetic replica of the native hypothalamic hormone
Development statusFDA-approved diagnostic use; fertility pump product discontinued

What it is

Gonadorelin is a synthetic form of native gonadotropin-releasing hormone (GnRH), the decapeptide the hypothalamus releases in pulses roughly every 60 to 120 minutes to drive pituitary LH and FSH secretion. It has been an FDA-approved drug since the 1970s-80s, historically marketed as Factrel for diagnostic pituitary function testing and as Lutrepulse, delivered by a dedicated pulsatile infusion pump, for inducing ovulation in women with hypothalamic amenorrhea. Lutrepulse has since been discontinued in the US; the diagnostic use persists.

Native GnRH, and gonadorelin as its synthetic copy, has a plasma half-life of only a few minutes. Its physiological effect depends entirely on pulsatile delivery: continuous, non-pulsatile exposure to GnRH or its agonists does not sustain LH/FSH release and instead downregulates the pituitary receptor, which is the exact mechanism GnRH agonist drugs like triptorelin exploit for suppression rather than stimulation.

What dosage information circulates?

Figures in this table summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Diagnostic pituitary testing (approved, Factrel)Injection (single test dose)Per FDA labelSingle doseN/AFDA-approved prescribing information
Ovulation induction (discontinued, Lutrepulse)Pulsatile IV infusion pumpPhysiological pulse patternApproximately every 60–120 minutesPer treatment cycleFDA-approved (product discontinued in the US)
Fertility/testicular support during TRT, off-labelSubcutaneous100–300 mcg per dose2–3 times weeklyOngoing, alongside testosterone therapyCommunity / vendor / practitioner reported

Native GnRH and gonadorelin work through pulses roughly every 60 to 120 minutes; a dose given every few days is separated by roughly 30 to 80 times that interval. No dedicated randomized trial of the twice- or thrice-weekly injection schedule was located to check the circulating regimen against.

Potential benefits and research applications

Diagnostic testing of pituitary function, the enduring FDA-approved use

A single dose of gonadorelin (Factrel) is used clinically to test whether the pituitary can appropriately release LH and FSH in response to GnRH stimulation, aiding diagnosis of pituitary versus hypothalamic causes of reproductive hormone disorders.

Evidence: has been shown in FDA-approved clinical use (Tier 1, published human clinical evidence, approved indication).

Inducing ovulation via pulsatile delivery, an approved but discontinued use

Lutrepulse, a dedicated pulsatile infusion pump delivering gonadorelin in a physiological pulse pattern, was FDA-approved to induce ovulation in women with hypothalamic amenorrhea. This product has since been discontinued in the US.

Evidence: was shown in FDA-approved clinical use (Tier 1, published human clinical evidence); the product itself is no longer available, and the pulsatile delivery method it depended on is not what circulates today.

Preserving fertility and testicular function during TRT, an off-label extrapolation without a dedicated trial

Gonadorelin is widely used off-label during testosterone replacement therapy, given by intermittent subcutaneous injection two to three times weekly, intended to keep the hypothalamic-pituitary-gonadal axis active. The rationale is drawn from GnRH physiology, not a trial of this specific regimen.

Evidence: has been reported anecdotally and by practitioners (Tier 5-6); has not been established by any dedicated randomized, placebo-controlled trial, and the dosing schedule used does not reproduce the roughly hourly pulse the hormone’s mechanism depends on.

How it is actually used off-label now

Outside its original approved uses, gonadorelin is now widely used off-label in testosterone replacement therapy protocols, given by intermittent subcutaneous injection two to three times per week, intended to keep the hypothalamic-pituitary-gonadal axis and testicular function active during exogenous testosterone administration. This specific off-label protocol, periodic subcutaneous gonadorelin during TRT, does not have a dedicated randomized, placebo-controlled trial establishing its efficacy for preserving fertility or testicular size in the sources reviewed for this entry; the rationale is drawn from GnRH physiology rather than a trial of this specific regimen.

This is a meaningful pharmacological mismatch worth stating plainly: the hormone’s entire mechanism depends on a pulse roughly every one to two hours, and a subcutaneous injection two or three times a week does not reproduce that pattern. Whether an intermittent, widely spaced injection meaningfully activates the same pathway a physiological GnRH pulse generator does is not established by a trial designed to test it.

What is not known

Whether gonadorelin given two to three times weekly by subcutaneous injection, the common off-label TRT-adjunct protocol, preserves fertility or testicular function as intended. No dedicated randomized trial of this specific regimen was located.

Long-term outcomes, including sperm parameters and testicular volume, from this off-label use pattern specifically, as distinct from the original approved pulsatile-pump indication.

Frequently asked questions

What is gonadorelin?

Gonadorelin is a synthetic form of native GnRH, an FDA-approved decapeptide historically used for diagnostic pituitary testing and, via a dedicated pump, to induce ovulation.

How does gonadorelin work?

It stimulates the pituitary to release LH and FSH, but only when delivered in pulses roughly every 60 to 120 minutes, matching how the hypothalamus naturally releases it. Continuous or infrequent exposure does not sustain that stimulation.

What dosage has been studied?

The approved diagnostic use is a single test dose. The discontinued fertility indication used a dedicated pulsatile pump delivering physiological pulses. No dedicated trial of the twice- or thrice-weekly injection schedule used off-label in TRT was located.

What dosage commonly circulates online?

Circulating TRT-adjunct protocols describe 100 to 300 micrograms subcutaneously, two to three times weekly. This interval is roughly 30 to 80 times longer than the natural pulse frequency the hormone’s mechanism depends on.

Has gonadorelin been studied in humans?

Yes, extensively, for its original approved diagnostic and pulsatile-pump fertility uses. No dedicated randomized trial of the intermittent TRT-adjunct injection schedule was located.

Is gonadorelin approved for use?

Yes, as Factrel, for diagnostic pituitary function testing. The pulsatile-pump fertility product (Lutrepulse) has been discontinued in the US.

What routes of administration are reported?

The diagnostic use is a single injection. The discontinued fertility product used a dedicated pulsatile infusion pump. Off-label TRT use is intermittent subcutaneous injection.

Does gonadorelin preserve fertility during TRT?

This has not been established by a dedicated trial. The rationale rests on GnRH physiology, but the twice- or thrice-weekly injection schedule commonly used does not reproduce the hourly pulse pattern the hormone’s effect depends on.

What side effects have been reported?

The approved diagnostic use has a well-characterized safety profile in clinical settings. A comprehensive side-effect profile specific to the off-label TRT-adjunct injection schedule was not established in the sources reviewed for this entry.

What remains unknown about gonadorelin?

Whether the common off-label TRT-adjunct protocol, given two to three times weekly, preserves fertility or testicular function as intended, and long-term sperm and testicular-volume outcomes from that specific use pattern.

Bottom line

Gonadorelin is a genuinely FDA-approved hormone with a real diagnostic use and a discontinued fertility application that depended on a dedicated pulsatile pump. Its now-common off-label role in TRT protocols asks it to do a fundamentally different job, intermittent injection instead of physiological pulsing, and that specific regimen has never been tested in a dedicated trial. The pharmacological mismatch between the mechanism and the schedule is real and unresolved.

Related entries: hCG, human chorionic gonadotropin.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Fertility/testicular support during TRT, generalSubcutaneous100 to 300 mcg per dose2 to 3 times weeklyOngoing, alongside testosterone therapy

Circulating TRT-adjunct dosing describes 100 to 300 mcg subcutaneously, 2 to 3 times per week. Native GnRH and gonadorelin work through pulses roughly every 60 to 120 minutes; a dose given every few days is separated by roughly 30 to 80 times that interval. The original approved fertility indication used a dedicated pump delivering an actual physiological pulse pattern, not an intermittent injection, and no trial of the twice- or thrice-weekly injection schedule was located to check the circulating regimen against.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Share thisFacebookXEmail